Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

NCT00540943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Colorectal

Interventions

DRUG: Pazopanib
DRUG: Cetuximab
DRUG: Irinotecan

Sponsor

GlaxoSmithKline